




The Evaluation of Placental Inflammation 
via the Genomic Inflammatory Index (GII) in 
Relation to Key Perinatal Factors 
 
Kirsi Sophia Oldenburg  
Honors Thesis ENHS 
Department of Environmental Sciences and Engineering 
Gillings School of Global Public Health 




Dr. Rebecca Fry 
Dr. Julia Rager 





 Inflammation in utero is associated with a variety of adverse health outcomes 
experienced by the offspring, such as forms of cerebral palsy and autism. Identifying and 
understanding what may be causing the in utero inflammation is vital for attempting to mitigate  
exposure to inflammation by the fetus. The objective of this study was to create a genomic 
inflammatory index (GII) that can be utilized to effectively evaluate and quantify inflammation 
levels in the placenta. For this study, 386 placentas from the Extremely Low Gestational Age 
Newborn (ELGAN) cohort, with sufficient data on mRNA levels, were assessed. The GII 
consists of a score derived from 14 inflammation-related genes selected for their established role 
in pro-inflammatory signaling pathways. The GII showed variance in placental inflammatory 
levels across subjects. Crude and adjusted models were used to examine the relationship between 
47 perinatal factors and the GII. Significant differences in inflammatory levels indicated by the 
GII were observed between Black mothers and White mothers, and between those who took 
steroids and those who did not take steroids while in labor at the hospital. It is anticipated that 
the GII will provide a novel genomics tool for quantifying placental inflammation, allowing for 
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The placenta is a vital organ for fetal development that undergoes changes throughout the 
entire span of pregnancy. The placenta begins to develop after fertilization, emerging from the 
outer wall of the blastocyst. The placenta serves a variety of roles, including hormone 
production, oxygen and nutrient transfer, and waste elimination, while also acting as a barrier 
against the mother’s immune system, chemical toxicants, and xenobiotics (1). Overall, the health 
of the fetus is largely dependent upon the proper functioning of the placenta (1, 2). Due to the 
placenta’s integral role in development, placental physiology has been tied to lifelong effects on 
the offspring (1, 2). In fact, phenotypes of the placenta are predictive of chronic conditions 
experienced later-in-life by the fetus, such as coronary heart disease and Hodgkin’s lymphoma 
(3-5). 
The placenta is of particular interest to the growing field of the developmental origins of 
health and disease hypothesis (DOHaD). DOHaD explores the later-in-life health effects 
associated with exposures by the fetus and neonate (6, 7). When the placenta is analyzed, it can 
be excised from the maternal or fetal side with different biological interpretations. Since the fetal 
side of the placenta is derived from the zygote, the fetus and the villous chorion share the same 
genetic composition (8). The placenta can serve as an unique indicator of what the fetus was 
exposed to in utero as well as the resulting gene expression and epigenetic alterations (9-16).  
In animal models, intrauterine inflammation has been tied to modified neurobehavioral 
functioning of the offspring, altered white matter development in the brain, acute brain injury, 
disruption of serotonin regulation, and altered gene expression (17-20). Adverse impacts of in 
utero inflammation have also been found in human cohorts, with data from the Extremely Low 
Gestational Age Newborn (ELGAN) cohort reporting that inflamed placentas were associated 
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with an increased risk of developing diparetic cerebral palsy later in life (at ~24 months post-
term equivalent) (21). Additional studies also found associations between prenatal inflammatory 
exposure and cerebral palsy in both preterm and term cohorts (22, 23). A cohort of children born 
at the New York Methodist Hospital demonstrated an association between acute placental 
inflammation and an increased risk for autism spectrum disorder (24). Combined, preterm birth 
and chorioamnionitis were found to increase the odds ratio for attention deficit hyperactivity 
disorder (ADHD) and neurodevelopmental disabilities in children (25). Overall, exposure to 
inflammatory stimuli is likely accountable for, or greatly contributes to, the development of a 
vast number of adverse health outcomes in childhood and later life.  
In utero inflammation and its precursors may be evaluated through the placenta. The 
presence of acute chorioamnionitis, and other histological markers of inflammation, is used as an 
indicator of intra-amniotic inflammation (26). Identifying acute chorioamnionitis involves 
histological evaluation of the amnion, chorionic connective tissue, or chorionic plate for 
abundantly distributed infiltration of both fetal and maternal neutrophils (27, 28). Histological 
evaluations of inflammation are quite useful in terms of determining whether or not there is 
inflammation in the placenta, however, the effectiveness of using histological evaluations for 
determining varying grades of inflammation has been questioned (26, 27). Alternatively, 
exposure to inflammatory stimuli can be identified by assessing the upregulation of 
proinflammatory genes, through an analysis of mRNA levels, such as the tumor necrosis factor-a 
(TNF-a) (29-31). Potential causes of in utero inflammation have been identified, with maternal 
demographics, such as obesity and infections, being the major perpetrators (26, 32-35). Of 
concern is the association between in utero inflammatory exposure and a variety of adverse 
health outcomes experienced by the offspring as summarized above.  
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The first aim of this study was to develop a tool for quantifying exposure to inflammation 
in the placenta in order to address shortcomings with popular histological evaluations of 
inflammation. Using the ELGAN study cohort, a Genomic Inflammatory Index (GII) was 
developed by assessing the mRNA expression within the placenta. The GII represents a 
composite measure of pro-inflammatory gene expression across fourteen genes. The second aim 
of this study was to use the GII to identify modifiable and non-modifiable maternal antecedents 
associated with increased pro-inflammatory gene expression. Understanding which maternal 
antecedents significantly impact inflammatory gene expression can inform intervention efforts to 
both prevent and decrease inflammation in the placenta, with potential positive impacts on later 





The ELGAN Cohort 
Cohort characteristics and study design have been detailed extensively elsewhere (36). 
Enrollment into the original ELGAN cohort began in 2002, and continued until 2004. 
Participants consist of infants born prior to 28 weeks’ gestation (n = 1506) and their mothers (n = 
1249). Pregnant women at 14 medical centers in the United States were recruited, with the 
Institutional Review Board at each medical center approving of the study. Maternal consent for 
participation was granted either upon admission to the hospital, or shortly after giving birth. 
Demographic and pre-pregnancy variables were collected after birth by a trained research nurse 
using a structured questionnaire. Additional information was also collected using medical 
records.  
 The perinatal factors identified in this study were gathered from the maternal medical 
records and the maternal interview. Antecedents of interest consisted of non-modifiable and 
modifiable perinatal factors previously analyzed for their association with positive child health, 
with the addition of more maternal medications and diseases screened for in the maternal 
interview (37, 38). In total, 47 antecedents were identified, with 10 maternal demographic 
antecedents, 19 maternal medication antecedents, 14 maternal diseases, and 4 maternal medical 
conditions (Supplement 1).  
 
Placenta Tissue Collection 
Of the 1249 ELGAN cohort mothers, 450 donated placentas. From these, 386 placentas had 
sufficient demographic data, passed quality assessment/quality control (QA/QC) steps described 
below, and were analyzed for mRNA expression.  
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 As detailed previously, placentas were biopsied within hours of delivery (39, 40). In 
brief, the appropriate sampling area was identified and the amnion was removed to reveal the 
chorion. Less than one gram of the base of the chorion, consisting of fetally derived tissue, was 
collected into a 2 mL cryogenic vial. The vials were placed in liquid nitrogen and stored at -80 
°C before and after being shipped to the University of North Carolina at Chapel Hill (UNC). For 
processing, 0.2 g was sliced from the sample and washed with 1x phosphate-buffered saline. 
Lysed tissue for nucleic acid extraction was formed by homogenizing the slices with lysis buffer 
and Buffer RLT (Qiagen, Germantown, MD).  
 
mRNA Extraction and Sequencing  
The AllPrep DNA/RNA/miRNA Universal kit (Qiagen) was used to isolate RNA 
molecules greater than 18 nucleotides in length. RNA quality and quantity were determined 
using LabChip (Perkin Elmer) RNA integrity scores and DV200 values. A QuantSeq 3′ mRNA-
Seq Library Prep Kit (Lexogen) was used to conduct a genome-wide mRNA expression analysis. 
One lane of the Illumina Hiseq 2500 was used to sequence and pool (single-end 50 bp) RNA-
sequencing libraries, which were prepared using Sciclone G3 (Perkin Elmer). The sequencing 
reads produced by the Illumina Hiseq 2500 were aligned to the GENCODE database v30, and 
arranged with Salmon (version 0.11.3) (41, 42). In total there were 37,268 unique human RNA 
transcripts used for further analysis. 
 
Normalization of Count Data and Generation of GII 
Aligned count data were used for data processing and statistical analyses. Count data 
were first filtered to exclude universally lowly expressed transcripts, requiring that > 25% of the 
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samples be expressed at signals above the overall median signal intensity, as done in previous 
genome-wide mRNA analyses (43-47). This resulted in a total of 10,408 mRNA transcripts. Of 
the 390 placentas evaluated, two samples were removed due to having all zero counts. Quality 
assessment and quality control (QA/QC) was conducted on the count data using both 1) 
calculation and visualization of principal components via the prcomp function, and 2) 
hierarchical clustering, including calculation of distance metrics and visualization, using the 
hclust function. Following removal of two outliers, the final analysis sample of the same n=386 
subjects was constructed. The DESeq2 package (v1.24.0) was used to normalize the count data 
using median signal intensity across all 10,408 genes (48).  
 
Identifying Candidate Genes to Comprise the GII   
The “HALLMARK_INFLAMMATORY_RESPONSE” gene set (Hallmark Gene Set, n 
= 200), version 5.0, provided by the GSEA and MSigDB Team was utilized as a baseline list of 
inflammation related genes (49-51). The entire list of detectable genes above the low expression 
cut-off (n = 10,408) in the ELGAN placentas was compared to the Hallmark Gene Set to 
determine direct overlap between the two sets. A subsequent list of 102 genes was formed 
(Supplement 2). Using the searchable human gene database, GeneCards, each of the 102 genes 
were evaluated for being pro-inflammatory or anti-inflammatory (52). Specifically, only the 
“Summaries” and “Function” sections of GeneCards were used to evaluate inflammatory 
functions related to each gene. If an inflammatory relationship was mentioned, but the 
relationship was not specified as pro- or anti- inflammatory, the gene was further analyzed using 
PubMed. A final list of fourteen pro-inflammatory related genes met our criteria. These fourteen 
genes are: C-C motif chemokine ligand 2 (CCL2); CD14 molecule (CD14); chemerin 
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chemokine-like receptor 1 (CMKLR1); colony stimulating factor 1 (CSF1); eukaryotic translation 
initiation factor 2 alpha kinase 2 (EIF2AK2); coagulation factor III, tissue factor (F3); 
interleukin 18 receptor 1 (IL18R1); interleukin 1 receptor type 1 (IL1R1); interleukin 4 receptor 
(IL4R); interferon regulatory factor 1 (IRF1); lysophosphatidic acid receptor 1 (LPAR1); 
oxidized low density lipoprotein receptor 1 (OLR1); toll like receptor 2 (TLR2); toll like receptor 
3 (TLR3).   
The normalized mRNA counts of the n=14 proinflammatory genes identified above for 
n=386 subjects were extracted. A genomic inflammatory index (GII) was calculated as follows: 
GII= log[sum(count of all 14 normalized genes)+1]. One unit was added to each subjects’ 
mRNA normalized counts due to ten subjects having a sum of zero, since log of zero is 
undefined. All of the above statistical analyses were conducted in R (v3.6.1). 
 
Evaluation of the GII in Relation to Perinatal Factors 
Demographic antecedents were coded as follows: non-ordinal categorical variables 
included race (White, Black, Asian, Native American, Mixed race, Other), maternal age (<21, 
21-35, 35+ at the time of birth), insurance status (HMO/private insurance, self-pay, public 
insurance, no insurance), and pre-pregnancy BMI (Underweight, normal, overweight, obese). 
Ordinal categorical variables included maternal education (1: ≤ 12, 2: 13-15, 3: ≥16) and 
plurality (1,2,3+). Binary variables included Hispanic ethnicity (yes/no), marital status (married/ 
not married), smoked during pregnancy (yes/no), use of IVF for the index pregnancy (yes/no), 
and fetal sex (male/female). Maternal diseases/conditions and medications were coded as 
follows: binary variables included use of NSAID during pregnancy (yes/no); use of antibiotic 
during pregnancy (yes/no); use of aspirin during pregnancy (yes/no); cerclage (yes/no;, any 
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cerebral spinal fluid infection during pregnancy (yes/no); use of antibiotic during current hospital 
admission (yes/no); use of antenatal corticosteroid (ACS) during current hospital admission 
(yes/no); use of magnesium sulfate (for preeclampsia/ pregnancy-induced hypertension) during 
current hospital admission (yes/no); use of magnesium sulfate (for tocolysis) during current 
hospital admission (yes/no); use of insulin during current hospital admission (yes/no); use of 
steroids (not for promoting lung maturity) during current hospital admission (yes/no); presence 
of sepsis during current hospital admission (yes/no); maternal discharge for pregnancy-induced 
hypertension/preeclampsia/toxemia (yes/no); maternal discharge for hemolysis, elevated liver 
enzymes, low platelet count (HELLP) syndrome (yes/no), discharge diagnosis of 
chorionitis/chorioamnionitis (yes/no). Continuous variables included highest temperature during 
the hospital admission for giving birth and highest white blood cell count during the hospital 
admission for giving birth. Where there was data for the presence of a condition, and condition-
specific medication use, a three-level non-ordinal variable was created: pre-pregnancy asthma 
(no, yes and took medication, yes and took no medication), during pregnancy UTI (no, yes and 
took medication, yes and took no medication), during pregnancy proteinuria (no, yes and took 
medication, yes and took no medication), during pregnancy STD (no, yes and took medication, 
yes and took no medication), during pregnancy vaginal infection (no, yes and took medication, 
yes and took no medication), during pregnancy fever (no, yes and took medication, yes and took 
no medication), during pregnancy flu (no, yes and took medication, yes and took no medication), 
during pregnancy pneumonia (no, yes and took medication, yes and took no medication), during 
pregnancy toxemia (no, yes and took medication, yes and took no medication), and pre-
pregnancy diabetes (no, yes and took medication, yes and took no medication). Clinical and 
histological evaluations of inflammation were coded as: grade of chorion/decidua inflammation 
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(none-minimal/mild-severe), any grade of inflammation in the chorion or amnion (yes/no), and 
moderate to severe indicators of inflammation in the chorionic plate or chorion or umbilical cord 
or fetal stem vessels [CCUFV] (yes/no).  
Linear regression models were fit with the GII as the dependent variable and various 
antecedents as the independent variable, thus resulting in a beta estimate representing the mean 
difference in GII comparing index to reference group of the antecedent. First, unadjusted models 
were run to examine crude relationships between GII and maternal antecedents. Significant 
relationships were defined a p<0.05 for the mean difference in GII estimate. If the crude estimate 
for an antecedent was significant adjusted models were run controlling for maternal BMI, 
maternal insurance, fetal sex, smoking during pregnancy, maternal marital status and maternal 
race. Covariates were selected for their known relationship to placental inflammation or 
significance in crude models (53-55). In adjusted models, significance was also defined as 
p<0.05 for the mean difference in GII estimate. Regression modelling was conducted in SAS 





Study Population Characteristics 
This cohort of 386 women included 235 (61.5%) White women, 112 (29.3%) Black women, 5 
(1.3%) Asian women, 4 (1.1%) Native American women, 12 (3.1%) mixed race women, and 14 
(3.7%) women who identified their race as “Other” on the maternal questionnaire. The majority 
(91.7%) of mother’s identified as non-Hispanic. Just over two-thirds (67.4%) of the cohort were 
between 21 and 35 years old, with an almost equal number of women having either completed 
their education up to and including 12th grade (39.2%) or completed at least a college degree 
(38.4%). The first and second most common insurance types were HMO or Private (65.3%) and 
Public Insurance (31.8%) respectively. A majority of the women (57%) were not married at the 
time of birth, and the most common BMI was in the Normal category (53.4%). About ten percent 
(10.8%) of the women had smoked during pregnancy. A total of 226 of the women had a 
singleton gestation in their participatory pregnancy, with 55 women utilizing IVF or ICSI for 
conception of their participatory pregnancy (Table 1).  
Table 1. Study Population Characteristics (n=386) of ELGAN Cohort Mother’s with Placental 
Samples Analyzed for mRNA Expression   




Median Min Max IQR 
Race  
       White 235 (61.5%) 5.05  0 8.98 2.25 
       Black 112 (29.3%) 5.92  0 8.61 2.35 
       Asian 5 (1.3%) 5.57  3.03 5.99 1.69 
       Native American 4 (1.1%) 5.04  3.90 6.91 0.776 
Mixed 12 (3.1%) 5.79  3.13 7.32 2.40 
Other 14 (3.7%) 4.97  2.00 6.88 1.20 
Missing 4      
Hispanic  
No 354 (91.7%) 5.26  0 8.98 2.43 
Yes 32 (8.3%) 5.33  2.00 7.94 2.49 
Maternal Age (Years)  
<21 44 (11.4%) 5.64  0 8.47 2.53 
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21-35 260 (67.4%) 5.20 0 8.98 2.49 
>35 82 (21.2%) 5.25  0 7.86 2.12 
Maternal Education 
(Years of Education) 
 
≤ 12 147 (39.2%) 5.43  0 8.30 2.72 
13-15 84 (22.4%) 5.19  0 8.47 2.34 
≥ 16 144 (38.4%) 5.14  0 8.98 1.14 
Missing 11      
Insurance  
HMO or Private 247 (65.3%) 5.17  0 8.98 2.32 
Self-Pay 5 (1.3%) 5.35  2.74 5.63 0.716 
Public Insurance 120 (31.8%) 5.67  0 8.47 2.62 
No Insurance 6 (1.6%) 5.22  3.19 6.57 1.86 
Missing 8      
Marital Status  
Not Married 166 (43.0%) 5.58  0 8.61 2.69 
Married 220 (57.0%) 5.15  0 8.98 2.13 
Pre-Pregnancy BMI  
Underweight 26 (7.0%) 4.42  1.19 7.15 3.16 
Normal  199 (53.4%) 5.38  0 8.98 2.55 
Overweight 67 (17.9%) 5.40  0 7.34 1.90 
Obese 81 (21.7%) 5.19  0 8.47 2.20 




No 338 (89.2%) 5.20  0 8.98 2.32 
Yes 41 (10.8%) 5.56  0 8.30 2.18 
Missing 7      
Plurality  
1 226 (61.1%) 5.42 0 8.61 2.59 
2 118 (31.9%) 5.10 0 8.98 2.09 
3+ 26 (7.0%) 5.23 0 7.85 2.13 
Missing 16      
IVF or ICSI  
No 41 (42.7%) 4.95  0 7.12 1.57 
Yes 55 (57.3%) 4.81  0 8.98 1.95 
Missing 290      
*Percentage of non-missing values  
 
GII and the Study Population 
The placentas in this study displayed a range of mRNA expression across the 14 genes used to 
calculate the GII (Figure 1). In addition, hierarchical clustering showed that the genes IL4R and 
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EIF2AK2 had the most similar z-score standardized mRNA counts across subjects (Figure 1). 
The GII values ranged from 0 to 8.98 with the data from all 386 women being slightly negatively 
skewed. The median GII was 5.29 (Figure 2).  
An examination of the 14 genes and their expression for the ELGAN subject with the 
maximum GII (8.98) showed the highest expression for F3 (Figure 3A). F3 is involved with 
blood coagulation cascades and its expression can be induced by mediators of inflammation such 
as cytokines and endotoxins (52). Additionally, the subject with the maximum GII had a greater 
z-score standardized mRNA count than at least 50% of the other subjects for all but one of the 
genes, IRF1, with F3 and LPAR1 being over eight standard deviations greater than the mean GII 
(Figure 3B). Meanwhile, the subject with the minimum GII had all zero counts for each of the 
fourteen GII genes (Supplement 3).  
  
 
Figure 1. Heat map of z-score standardized mRNA counts. This heat map illustrates the z-
score standardized mRNA counts for each of the genes used to calculate the GII across all 
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genes and subjects was performed. Blue represents a lower relative expression level, while red 
represents a higher relative expression level. Genes are represented on the y axis and subjects 
on the x axis. 
 
 
Figure 2. Histogram showing the distribution of the GII for all 386 subjects. GII bins are 
marketed by “[” showing an included value, and “)” showing the non-included upper value 
of the bin (ie. with [0-1) the bin is comprised of any value including zero, up to, and not 






A: Bar chart of the log2 (Normalized mRNA Count + 1) for each of the 14 genes from the 
subject with the largest GII.  
























































































































Maternal Antecedents / Perinatal Factors: 
A total of 47 different perinatal factors were examined in relation to the GII. Those that 
displayed any significant association (either in the crude or adjusted models) are detailed below. 
The results of all comparisons can be found in the Supplemental Materials (Supplement 4).  
 
GII and Marriage 
In the unadjusted models the placental GII for mothers who were married was on average 0.4102 
counts (on a log scale; beta value = 0.4102) lower than the GII of mothers who were not married 
during pregnancy (p=0.0486; Figure 4A; Table 2). In the models adjusting for maternal BMI, 
maternal insurance, fetal sex, smoking during pregnancy, and maternal race, the mean difference 
in GII for marital status was no longer significant, with a beta value of -0.2981 and p-value of 
0.2431 (Table 2).  
 
GII and Fever  
The placental GII for mothers who had a fever during pregnancy and took fever medications was 
on average 0.8528 counts (on a log scale) lower than the GII of mothers who did not have a fever 
during pregnancy, and this mean difference was statistically significant (p=0.0486) in the 
unadjusted models (Figure 4B; Table 2). In the adjusted models there was no longer a 
significant difference for any of the fever classifications (Table 2). The comparison of those who 
had a fever and did not take medications versus those who did not have a fever was insignificant 
in both the unadjusted and adjusted models (p= 0.3952 and p=0.3905, respectively; Table 2).  
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GII and Steroids 
A significant mean difference in GII was found between women who were given steroid(s) (not 
for promoting lung maturity) when they were in the hospital giving birth versus women who 
were not given such steroids in both the adjusted and unadjusted models (p=0.0423 and p=0.023, 
respectively; Figure 4C; Table 2). The beta values in the unadjusted and adjusted models were 
0.6753 and 0.7501, respectively, signifying that those who were given a steroid had a higher GII 
on average (Table 2).  
 
GII and Race 
In both the unadjusted and adjusted models the placental GII for mothers who identified as Black 
was on average 0.8701 and 0.9707 counts (on a log scale) higher, respectively, than the GII of 
mothers who identified as White (p<0.001; Figure 4D; Table 2). 
Table 2. Beta values, standard error and associated p-values of crude linear regressions and 
adjusted multivariate linear regressions of GII onto maternal antecedents. Only maternal 
antecedents that were significant in the unadjusted modeling are shown. Beta values represent 
the predicted change of GII between the chosen reference subgroup and the remaining 
subgroups of a maternal antecedent category. The reference subgroup for race was those who 
identified as white, the reference subgroup for steroid was those who did not receive a steroid 
(not for promoting lung maturity) during the hospital admission for giving birth, the reference 
subgroup for marriage was those who were married, and the reference subgroup for fever was 
those who did not report having a fever during pregnancy. Adjusted for maternal BMI, 
maternal insurance, fetal sex, smoking during pregnancy, maternal marital status, and maternal 














White 4.90 - - - - - - 
Black 5.77 0.8701 0.196 <0.001 0.9707 0.2367 <0.0001 
Steroid* 
No 5.08 - - - - - - 
Yes 5.76 0.6753 0.3325 0.0423 0.7501 0.33 0.023 
Marital Status 
Not Married 5.39 - - - - - - 
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Married 4.98 -0.4102 0.1787 0.0217 -0.2981 0.2554 0.2431 
Fever During Pregnancy 
No 5.18 - - - - - - 
Yes (No Meds) 4.12 -1.0515 1.2366 0.3952 -1.0417 1.2132 0.3905 
Yes (Meds) 4.33 -0.8538 0.4329 0.0486 -0.5897 0.4416 0.1817 





Figure 4 A – D. Boxplots of unadjusted results that were statistically significant. 4A) Boxplot 
of the GII for those who were married and not married. 4B) Boxplot of the GII for different 
fever classifications during pregnancy. 4C) Boxplot of the GII for those who were 
administered a steroid (not for lung maturity) while giving birth versus those were not. 4D) 
Boxplot of the GII for each race recorded.   
 
GII and Clinical/Histological Indicators of Inflammation  
We next set out to compare the GII values to other measures of inflammation in placentas. There 
was not a significant mean difference in GII between cases of any inflammation or high grades 
of inflammation versus cases of low grade inflammation or no inflammation in the following 
















































(beta value= 0.096, p=0.6066), Any Inflammation in the Chorion or Amnion (beta value= 
0.0114, p=0.9512), Moderate to Severe Indicators of Inflammation in Any of the CCUFV (beta 
value= 0.0644, p=0.7346; Table 3). While not statistically significant, each of the 
aforementioned clinical indicators of inflammation did have positive beta values in relation to 
GII, indicating a positive trend in GII scores for cases with any inflammation or high grades of 
inflammation. In addition, all but one of the markers of inflammation, and their subcategories, 
did not have direct overlap, showing variability in their measures (Table 4). Only the moderate 
to severe classification of inflammation in the chorion/decidua had a precise overlap with there 
being any marker of inflammation in the chorion or amnion. This is shown by 0% of the subjects 
who were marked as having moderate to severe chorion/decidua inflammation being recorded as 
no inflammation in the chorion or amnion for the respective variables in a cross tabulation 
(Table 4).  
Table 3. Beta values, standard error and associated p-values of crude linear regression models 
for histological and clinical markers of inflammation in the placenta. These markers included the 
grade of chorion/decidua inflammation, any grade of inflammation in the chorion or amnion, and 
moderate to severe indicators of inflammation in the chorionic plate or chorion or umbilical cord 
or fetal stem vessels [CCUFV].  
 Mean GII Unadjusted 
Beta Value Standard Error p-Value 
Chorion/Decidua Grade of 
Inflammation 
    
None to Minimal 5.12 - - - 
Mild to Severe 5.21 0.096 0.1864 0.6066 
Any Inflammation in the 
Chorion or Amnion 
    
No 5.15 - - - 
Yes 5.16 0.0114 0.1857 0.9512 
Moderate to Severe Indicators 
of Inflammation in Any of the 
CCUFV 
    
No 5.12 - - - 
Yes 5.19 0.0644 0.1901 0.7346 
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 Exposure to inflammatory stimuli in utero is associated with a variety of adverse later in 
life health outcomes (21-25, 56). It is a critical undertaking to understand what causes 
inflammation in utero, especially when considering maternal factors that are potentially 
modifiable. Currently, in utero inflammation is mainly evaluated through histological 
identification of inflammation, with quantification of the mRNA levels of inflammation related 
genes being an underused resource (26-31). In the present study we set out to develop an index 
that could quantify the presence of inflammation in the placenta at the transcriptome level and be 
used to evaluate antecedents of placental inflammation. There were three main findings: 1) the 
GII demonstrated a strong ability to capture variance in pro-inflammatory gene expression, 2) 
significant differences in inflammation detected via the GII were found for potential maternal 
antecedents of placental inflammation, and 3) there was a non-significant positive trend between 
the GII and histological markers of inflammation, with the histological markers of inflammation 
demonstrating inconsistencies in their determination.  
 In evaluating the GII, it was important to examine the extent to which the GII varied 
between subjects. A heat map of the mRNA count per gene by subject, and a model of the 
distribution of GIIs, were used to analyze the variance of GII within the cohort. In summary, 
both the heat map and the distribution of GIIs showed a range of GIIs, with a minimum of 0 and 
a maximum of 8.98, indicating differences in pro-inflammatory gene expression across the 
placentas analyzed. These results are consistent with current evaluations of placental 
inflammation used in the literature in that a) placental inflammation can be detected and 
analyzed and b) there are alternate levels, or amounts, of in utero inflammation (26-35). With 
this variance in GIIs comes the question as to what were the driving forces behind these 
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differences in the transcriptome level measure of inflammation. In the literature, maternal 
demographic factors, infections, and diseases are associated with placental inflammation, leading 
to an analysis of what maternal demographic factors and diseases experienced during pregnancy 
were associated with an increased GII in the present cohort (26, 32-35). 
 Two maternal antecedents were found to have a statistically significant mean difference 
in GII between subjects in only the unadjusted models. Being married significantly lowered the 
subjects’ GIIs in the unadjusted models, shown by a negative beta value, potentially signifying a 
protective effect of being married. Previous studies have shown a protective effect of being 
married on overall health and inflammation levels, albeit, other studies have warned of the 
importance of considering the quality of the marriage on overall health as well (57-60). In 
addition, a negative beta value was produced when comparing the GIIs of those with no fevers 
during pregnancy versus those who took fever medication for fevers that occurred during 
pregnancy, possibly showing an association between taking fever medications and a reduction in 
GII. Such a reduction in GII after taking fever medications for a fever could result from fever 
medications such as NSAIDs having anti-inflammatory affects. However, Tylenol is also a 
popular fever medication that does not have anti-inflammatory affects, highlighting the 
importance of knowing which specific type of fever medication these mothers took. Since in the 
adjusted models the associations between the GII, marital status, and fever classification were no 
longer significant, the relationships seen were likely driven by the confounders controlled for in 
the adjusted models, including insurance status and race.  
Two perinatal factors remained significant in relation to the GII in both the unadjusted 
and adjusted models: steroid use and race. Those who received a steroid (not for promoting lung 
maturity) while admitted for delivery had greater GIIs on average compared to mothers who did 
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not receive such steroids, signifying an increase in inflammation amongst those who received the 
steroids. As specified, these steroids were not for promoting lung maturity and instead were 
possibly given for flare-ups in asthma or autoimmune conditions such as lupus or rheumatoid 
arthritis. In which case the mothers may have been given prednisone or prednisolone: anti-
inflammatory corticoid steroids typically used for treating maternal inflammatory diseases (61, 
62). Even though the exact condition as for why the steroids were administered was not 
specified, the steroids were most likely supposed to have an anti-inflammatory effect which was 
not seen in the present study. What may have driven the increase in GII in those given steroids is 
the timing and reactionary use of the steroid, where the steroid was likely administered in 
response to an inflammatory event. At that point, inflammation related mRNA levels may have 
already been high and remained high as the placenta was removed, preventing the steroids from 
normalizing the inflammation levels.  
Another factor possibly accounting for the increased GII in those administered steroids 
during birth is where the steroids were metabolized and what their target was. Through 
pharmacokinetics, drugs are administered based on their metabolization and movement 
throughout the body. Drugs such as dexamethasone, which is given to promote fetal lung 
maturity, are known to not be metabolized by the placenta, allowing them to reach the fetus at 
high concentrations (61-63). Meanwhile, drugs such as prednisone and prednisolone do not reach 
the fetus at as high of concentrations, and are thus used to treat maternal diseases instead (61, 62, 
64). Since the steroids administered to the mothers were not for promoting lung maturity, their 
anti-inflammatory effects may not have reached the fetal side of the placenta where the samples 
used in this study were collected from. Thus, allowing for the fetal side of the placenta to remain 
inflamed despite the mothers being given steroids.   
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The maternal demographic, race, also remained statistically significant in the adjusted 
models. Specifically, Black mothers on average had a higher GII than White mothers. Racial 
disparities in placental pathology have been reported in previous studies (53, 54). For example, 
one study found that Black mothers of preterm infants had a higher adjusted odds of having 
chronic inflammation in the placenta at birth than White mothers (54). Proposed driving forces 
behind the differences in placental inflammation between White and Black mothers includes a 
mix of socioeconomic status, racial discrimination, stress levels, and the weathering hypothesis, 
which states that cumulative socioeconomic disadvantage has a deteriorating effect on the 
physical health of African American women (54, 65-67). Further research into the association 
between race and placental inflammation is warranted.   
Three clinical and histological evaluations of inflammation at birth in the ELGAN cohort 
were assessed using the GII: grade of chorion/decidua inflammation, any grade of inflammation 
in the chorion or amnion, and moderate to severe indicators of inflammation in the chorionic 
plate or chorion or umbilical cord or fetal stem vessels [CCUFV]. While there was no 
statistically significant increase in GII’s between mothers with no or low grades of inflammation 
versus mothers with inflammation or high grades of inflammation, there was a slightly positive 
trend. Interestingly, when comparing the clinical and histological evaluations of inflammation 
against one another there was not a direct overlap between a majority of like categories. This 
shows variability amongst the clinical/histological variables and possible inconsistencies in 
measurement, which have previously been reported in the literature (26, 27). A study by Redline 
et al. evaluated how well pathologists’ identifications of placental inflammatory lesions agreed. 
Overall, there was high agreement when simply determining if there was inflammation or not, 
however, when quantifying the grade or stage of inflammation the agreement became weak (27). 
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These results demonstrate the limitations of histological measurements and a need for alternative 
methods for quantifying inflammation. The lack of association between the clinical and 
histological evaluations of inflammation and the GII, and slight discrepancies in the 
clinical/histological evaluations themselves, calls for further investigation into these 
clinical/histological variables.    
The GII has strengths as a novel tool to evaluate inflammation in the placenta and has various 
ways to be improved. One strength of the GII is how the GII is a continuous and quantitative 
variable, allowing for a gradient in inflammation to be formed that could be used to analyze how 
varying levels of inflammation are related to antecedents of inflammation. Meanwhile, 
histological and clinical assessments of inflammation are ordinal and qualitative variables, 
causing less flexibility in analysis. A second major strength of the GII includes how the GII is 
comprised of mRNA transcript levels, versus histological evaluations, and is thus not subject to 
as grave of human error and opinion as chorioamnionitis may be (26, 27). Still, the results from 
this study and the GII in its current form are not without limitations. The ELGAN cohort consists 
of only extremely preterm newborns, which may limit generalizability of the GII. In addition, a 
few of the antecedents gathered from the maternal interview may be subject to social desirability 
bias, such as smoking during pregnancy. Another form of inconsistency may result from mothers 
not accurately recalling what diseases they had or what medications they took during pregnancy. 
Certain results may have been affected by low sample sizes, such as many of the diseases and 
medications reported, due to mothers not answering that portion of the survey or not having 
contracted such diseases during pregnancy. One limitation of the GII is how the mRNA levels 
may be representative of one point in time, in this case at birth, since gene expression and 
transcription can change throughout life. Histological determination of inflammation is also 
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subject to such a limit due to the change in protein levels through protein synthesis and 
degradation. Further work on the GII is warranted as certain antecedents associated with 
placental inflammation in the literature, such as maternal BMI, were not observed as causing a 
significant difference in GII in the present study (26, 32-35, 68).  
In summary, the GII represents a composite measure of pro-inflammatory gene expression 
across fourteen genes that was used to assess the influence of maternal antecedents on placental 
pro-inflammatory gene expression. Future directions and improvement plans for the GII include 
expanding the GII gene list to include additional genes used to evaluate inflammation, such as: 
caspase-1 (CASP1) and toll-like receptor 4 (TLR4) (35, 69, 70). These genes were originally not 
included in the GII because they were not found to be direct matches between the Hallmark Gene 
Set and the detectable mRNAs expressed in the ELGAN cohort placentas. A second 
improvement will involve adding additional socioeconomic variables as confounding variables to 
better understand what may be driving results to be significant or not in adjusted and unadjusted 
models. A final future direction will involve an in-depth comparison of the GII to 
chorioamnionitis and other inflammation variables collected form the ELGAN cohort, in 
addition to understanding and resolving any disconnect between the GII and the inflammatory 
variables. Overall, the long term goal is for the GII to serve as a biomarker of in utero 
inflammatory exposure with hopes of mitigating exposure to inflammatory stimuli and better 
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Supplement 2. List of genes that directly overlapped between the Hallmark Gene Set and the 
ELGAN detectable genes in the placenta (n = 102) 
 
Genes in both Hallmark Gene Set and ELGAN Gene Set  
A 
 








'CALCRL' 'CCL2' 'CD14' 'CD55' 'CD82' 'CDKN1A' 'CMKLR1' 'CSF1' 'CSF3R' 'CXCR6' 'CYBB'  
 
D 'DCBLD2'  
 
E 'EDN1' 'EIF2AK2' 
 
F 'F3'  
 




'HBEGF' 'HIF1A' 'HRH1' 
I 'ICOSLG' 'IFNAR1' 'IFNGR2' 'IL10RA' 'IL15RA' 'IL18R1' 'IL1R1' 'IL4R' 'INHBA' 'IRF1' 'ITGA5' 'ITGB8'  
 
K 'KCNJ2' 'KIF1B' 'KLF6' 
 
L 'LCP2' 'LDLR' 'LPAR1' 'LYN' 
 
M 'MET' 'MMP14' 'MSR1'   'MXD1' 'MYC'  
 
N 'NAMPT' 'NFKB1' 'NFKBIA' 'NMI' 'NPFFR2'  
 
O 'OLR1' 'OSMR'  
 
P 'P2RX4' 'P2RX7' 'PDE4B' 'PDPN' 'PLAUR' 'PSEN1' 'PTPRE' 'PVR'  
 
R 'RAF1' 'RASGRP1' 'RELA' 'RIPK2' 'RNF144B'  
 
S 'SCARF1' 'SELENOS' 'SEMA4D' 'SERPINE1' 'SGMS2' 'SLC11A2' 'SLC1A2' 'SLC28A2' 'SLC31A1' 'SLC31A




'TAPBP' 'TIMP1' 'TLR2' 'TLR3' 'TNFRSF1B' 'TNFSF10' 'TNFSF15' 'TPBG' 
 
 
Supplement 3. Normalized mRNA counts per gene and GII for the subject with the minimum GII 
and for the subject with the maximum GII 
Subj. Gene  
CCL2 CD14 CMKLR1 CSF1 EIF2AK2 F3 IL18R1 IL1R1 IL4R IRF1 LPAR1 OLR1 TLR2 TLR3 GII 
1 0.910 6.37 2.73 1.82 25.5 301 5.46 58.3 10.9 2.73 33.7 44.6 1.82 7.28 8.98 
2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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Supplement 4. Beta values, standard error and associated p-values of crude linear regressions and 


















White 4.90 - - - - - - 
Black 5.77 0.8701 0.196 <0.001 0.9707 0.2367 <0.0001 
Asian 4.91 0.0126 0.7713 0.987 0.2583 0.7691 0.737 
Native American 5.22 0.326 0.8606 0.7048 0.5311 0.8971 0.5538 
Mixed 5.42 0.5228 0.5051 0.3006 0.567 0.5191 0.2747 
Other 4.78 -0.117 0.4695 0.8032 -0.1434 0.5002 0.7743 
Hispanic        
No 5.15 - - - - - - 
Yes 5.24 0.0922 0.323 0.7752 - - - 
Maternal Age 
(Years) 
       
<21 5.32 0.2225 0.285 0.4349 - - - 
21-35 5.10 - - - - - - 




       
≤ 12 5.17 - - - - - - 
13-15 5.29 -0.0735 0.1029 0.4754 - - - 
≥ 16 5.02 -0.0735 0.1029 0.4754 - - - 
Insurance        
HMO or Private 5.12 - - - - - - 
Self-Pay 4.77 -0.347 0.7907 0.6608 - - - 
Public Insurance 5.25 0.1281 0.1948 0.5109 - - - 
No Insurance 4.83 -0.2929 0.7233 0.6855 - - - 
Marital Status        
Not Married 5.39 - - - - - - 
Married 4.98 -0.4102 0.1787 0.0217 -0.2981 0.2554 0.2431 
Pre-Pregnancy 
BMI 
       
Underweight 4.71 -0.4389 0.364 0.2279 - - - 
Normal  5.15 - - - - - - 
Overweight 5.06 -0.0866 0.2465 0.7255 - - - 
Obese 5.33 0.1865 0.23 0.4177 - - - 
Smoking During 
Pregnancy 
       
No 5.11 - - - - - - 
Yes 5.31 0.1998 0.289 0.4893 - - - 
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Plurality        
1 5.18 0.0941 0.2005 0.6387 - - - 
2 5.09 - - - - - - 
3+ 5.16 0.0775 0.3824 0.8393 - - - 
IVF or ICSI        
No 4.63 - - - - - - 
Yes 5.08 0.451 0.3316 0.1738 - - - 
Maternal Diseases and Subsequent Medications 
Asthma (Pre-
Pregnancy) 
       
No 5.16 - - - - - - 
Yes (No Meds) 4.70 -0.462 0.495 0.3506 - - - 
Yes (Meds) 5.05 -0.1124 0.2966 0.7047 - - - 
UTI        
No 5.14 - - - - - - 
Yes (No Meds) 6.37 1.4338 1.7554 0.4141 - - - 
Yes (Meds) 5.06 -0.085 0.2619 0.7456 - - - 
STD        
No 5.12 - - - - - - 
Yes (No Meds) 7.03 1.9102 1.24 0.1234 - - - 
Yes (Meds) 5.29 0.1698 0.4937 0.7308 - - - 
Vaginal Infection        
No 5.13 - - - - - - 
Yes (No Meds) 5.45 0.3183 0.7229 0.6597 - - - 
Yes (Meds) 5.13 -0.0012 0.2526 0.9961 - - - 
Fever        
No 5.18 - - - - - - 
Yes (No Meds) 4.13 -1.0515 1.2366 0.3952 -1.0417 1.2132 0.3905 
Yes (Meds) 4.33 -0.8538 0.4329 0.0486 -0.5897 0.4416 0.1817 
Flu        
No 5.18 - - - - - - 
Yes (No Meds) 4.35 -0.8333 0.4924 0.0906 - - - 
Yes (Meds) 4.22 -0.9642 0.7179 0.1793 - - - 
Pneumonia        
No 5.14 - - - - - - 
Yes (Meds) 4.88 -0.2587 1.017 0.7992 - - - 
Diabetes (Pre-
Pregnancy) 
       
No 5.13 - - - - - - 
Yes (No Meds) 7.32 2.1868 1.751 0.2117 - - - 
Yes (Meds) 5.17 0.0425 0.6249 0.9457 - - - 
Toxemia        
No 5.15 - - - - - - 
Yes (No Meds) 4.97 -0.1848 0.4243 0.6632 - - - 
Yes (Meds) 4.98 -0.1716 0.3859 0.6566 - - - 
CSF Infection        
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No 5.15 - - - - - - 
Yes 5.22 0.0741 0.3384 0.8267 - - - 
Highest Temp*        


















Sepsis*        
No 5.15 - - - - - - 








       
No 5.10 - - - - - - 





       
No 5.17 - - - - - - 
Yes 4.84 -0.3246 0.4338 0.4544 - - - 
Other Maternal Medications 
Antibiotics        
No 5.17 - - - - - - 
Yes 5.05 -0.362 0.2911 0.2137 - - - 
NSAIDs        
No 5.13 - - - - - - 
Yes 5.16 -0.0688 0.4406 0.876 - - - 
Aspirin        
No 5.13 - - - - - - 
Yes 5.22 -0.2076 0.4818 0.6666 - - - 
Antibiotics*        
No 5.16 - - - - - - 




       
No 5.35 - - - - - - 









No 5.14 - - - - - - 




       
No 5.22 - - - - - - 
Yes 5.09 -0.1349 0.1826 0.4601 - - - 
Insulin*        
No 5.10 - - - - - - 
Yes 5.78 0.6862 0.4235 0.1052 - - - 
Steroid (Not for 
Promoting Lung 
Maturity)* 
       
No 5.08 - - - - - - 
Yes 5.76 0.6753 0.3325 0.0423 0.7501 0.33 0.023 
Other Maternal Conditions 
Cerclage        
No 5.18 - - - - - - 
Yes 4.81 -0.3673 0.2801 0.1898 - - - 
Proteinuria        
No 5.14 - - - - - - 
Yes (No Meds) 5.17 0.0277 0.2971 0.9257 - - - 
Yes (Meds) 4.80 -0.341 0.563 0.5447 - - - 
Highest White 
Blood Cell Count* 
       
Change in GII per 
White Blood Cell 

















       
No 5.11 - - - - - - 
Yes 5.34 0.227 0.2309 0.3257 - - - 
**During hospital admission for giving birth  
 
